Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6936599
Estriol therapy for multiple sclerosis and other autoimmune diseases
expired -
US 6936431
Methods and compositions for inhibiting farnesyl transferase enzyme
expired -
US 6936701
Glycoconjugates and methods
expired -
US 6933108
Methods and compositions for use in the treatment of filovirus mediated disease conditions
expired -
US 6933279
Orally administered peptides to ameliorate atherosclerosis
expired -
US 6933142
HEC-G1CNAC6ST
expired -
US 6929910
Diagnostic and therapeutic methods using the H37 tumor suppressor gene
expired -
US 6930085
G-type peptides to ameliorate atherosclerosis
expired -
US 6929802
Method of cancer treatment
expired -
US 6929811
Monoamine oxidase (MAO) inhibitors and uses thereof
expired -
US 6930101
Thiazolopyrimidines useful as TNFΞ± inhibitors
expired -
US 6929796
Methods to treat undesirable immune responses
expired -
US 6929799
D-alanine racemase mutants of mycobacteria and uses therefore
expired -
US 6930084
Treating arthritis with TNF receptor releasing enzyme
expired -
US 6927285
Genes for human telomerase reverse transcriptase and telomerase variants
expired -
US 6923973
Peptide and DNA immunization against Coccidioides immitis infections
expired -
US 6924095
Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
expired -
US 6924118
Recombinant intracellular pathogen immunogenic compositions and methods for use
expired -
US 6924415
Transgenic mice comprising a constitutively-activated MEK5 and exhibiting cardiac hypertrophy and dilated cardiomyopathy
expired -
US 6921634
Replication competent hepatitus C virus and methods of use
expired -
US 6921664
Telomerase
expired -
US 6918927
Coated implantable medical device
expired -
US 6919425
Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
expired -
US 6919072
Methods and compositions for reducing collagen loss due to chronological aging in human skin
expired -
US 6916802
Amino ceramide-like compounds and therapeutic methods of use
expired -
US 6916816
Phenanthryl piperazinyl dicarboxylic acids as selective NMDA receptor modulating agents
expired -
US 6913755
Mutants of Streptococcal toxin A and methods of use
expired -
US 6914050
Stimulation of bone growth with thrombin peptide derivatives
expired -
US 6911178
Rh blood group antigen compositions and methods of use
expired -
US 6911466
AΞ²42 lowering agents
expired -
US 6911471
S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
expired -
US 6911324
Induction of beta cell differentiation in human cells
expired -
US 6911314
Screening for drugs that affect TNF receptor releasing enzyme
expired -
US 6911474
Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
expired -
US 6911532
Vertebrate apoptosis gene: compositions and methods
expired -
US 6908918
Antitumor agents
expired -
US 6908994
Collagen-binding proteins from enterococcal bacteria
expired -
US 6905873
Recombinant p53 adenovirus methods and compositions
expired -
US 6903076
Antihelminthic anthraquinones and method of use thereof
expired -
US 6902932
Helically organized silk fibroin fiber bundles for matrices in tissue engineering
expired -
US 6902933
Surface transfection and expression procedure
expired -
US 6903068
Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
expired -
US 6903135
Methods and products related to 16-HETE analogs
expired -
US 6902910
Death domain containing receptor 4
expired -
US 6902907
Cystic fibrosis gene
expired -
US 6899873
Method of forming micro-tubular polymeric materials
expired -
US 6899882
Endothelial cell growth factor methods of isolation and expression
expired -
US 6899895
Lamellar gels and methods for making and regulating
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory